CpG Methylation Analysis for Replicative Senescence Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing cellular aging in mesenchymal stromal cells lack reliable molecular markers, making it difficult to determine the replicative senescence status, which is crucial for cell therapy applications, as existing parameters like passage number and telomere length are not consistently reliable.
Innovation Solution
Determining the methylation status of specific CpG-dinucleotides, such as GRM7-CpG-site #1, CASR-CpG-site #1, PRAMEF2-CpG-site #1, SELP-CpG-site #1, CASP14-CpG-site #1, and KRTAP13-3-CpG-site #1, and comparing it to a reference methylation status to assess replicative senescence, using methods like methylation-specific PCR or bisulfite sequencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passage number and telomere length are used as markers for cellular aging, then assessment of replicative senescence is possible, but reliability and consistency of the assessment deteriorates
Solution Approach 1:
The patent transitions from using traditional parameters (passage number, telomere length) to measuring DNA methylation status at specific CpG dinucleotides. This parameter change enables reliable and precise assessment of replicative senescence by detecting epigenetic modifications that occur during cellular aging, directly resolving the contradiction between reliability and measurement precision.
2Reliability
If expression of senescence-associated beta-galactosidase is measured, then cells at senescent stage can be discerned, but quantitative measure for cellular aging is hardly provided
Solution Approach 1:
The patent replaces the qualitative enzymatic assay (beta-galactosidase expression) with a quantitative molecular measurement system based on DNA methylation analysis. This substitution transforms the assessment from a binary senescent/non-senescent distinction to a continuous quantitative measure of cellular aging, preserving the ability to discern senescent cells while adding precise quantitative information.
3Reliability
If karyotyping and SNP-arrays are used for analyzing cells in culture, then chromosomal abnormalities can be detected, but finding malignant subclone in heterogeneous mixture of cells becomes difficult
Solution Approach 1:
The patent focuses on specific local molecular markers (methylation status of particular CpG dinucleotides) rather than global chromosomal analysis. This local quality approach enables detection of subtle epigenetic changes in malignant subclones within heterogeneous cell populations, overcoming the limitation of bulk chromosomal analysis methods that average out rare aberrant cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a precise and reliable method to differentiate between early and late passage cells, correlating methylation status with passage number, enabling accurate assessment of cellular aging and potential for improved cell therapy outcomes.
Implementation Method 1
determining the methylation status of least one of the CpG-dinucleotides... wherein the methylation status of said CpG-dinucleotide linearly correlates with the replicative senescence status of said cell
Data Source
AI summary
The invention concerns methods and kits for determining the replicative senescence status of a cell, for identifying a cell culture which is suitable for therapeutic use, and for quantifying the reprogramming efficiency of induced pluripotent stem cells, wherein the methylation status of at least one of the CpG-dinucleotides within a region of about 50,000 bp upstream and/or downstream of at least one of the CpG-dinucleotides selected from the group consisting of GRM7-CpG-site #1, CASR-CpG-site #1, PRAMEF2-CpG-site #1, SELP-CpG- site #1, CASP14-CpG-site #1 and KRTAP13-3-CpG-site #1 for multiple corresponding DNA molecules is determined and compared to a reference methylation status.